MARKET

CLVS

CLVS

Clovis Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.29
+0.19
+3.11%
Opening 11:51 04/06 EDT
OPEN
6.36
PREV CLOSE
6.10
HIGH
6.40
LOW
6.04
VOLUME
1.93M
TURNOVER
--
52 WEEK HIGH
25.88
52 WEEK LOW
2.930
MARKET CAP
461.99M
P/E (TTM)
-0.8456
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLVS stock price target is 13.53 with a high estimate of 32.00 and a low estimate of 3.000.

EPS

CLVS News

More
  • Clovis Oncology (CLVS) Gains As Market Dips: What You Should Know
  • Zacks · 2d ago
  • Clovis: Coronavirus Bear Market Overreaction
  • Seeking Alpha - Article · 03/26 21:59
  • Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report?
  • Zacks · 03/25 16:30
  • Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
  • Zacks · 03/20 14:36

Industry

Biotechnology & Medical Research
+3.91%
Pharmaceuticals & Medical Research
+3.17%

Hot Stocks

Symbol
Price
%Change

About CLVS

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
More

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.